Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 23637557)

1.

Current Perspectives on rosuvastatin.

Hu M, Tomlinson B.

Integr Blood Press Control. 2013 Apr 18;6:15-25. doi: 10.2147/IBPC.S34814. Print 2013.

2.

Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?

Fabbri G, Maggioni AP.

Adv Ther. 2009 May;26(5):469-87. doi: 10.1007/s12325-009-0025-6. Epub 2009 May 14. Review.

PMID:
19444394
3.

Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).

Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.

Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22.

5.

Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.

Olsson AG, McTaggart F, Raza A.

Cardiovasc Drug Rev. 2002 Winter;20(4):303-28. Review.

PMID:
12481202
6.

Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.

Pedersen TR.

Am J Cardiovasc Drugs. 2010;10 Suppl 1:10-7. doi: 10.2165/1158822-S0-000000000-00000. Review.

PMID:
21391729
7.
8.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
9.

Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.

Marrs JC, Saseen JJ.

Pharmacotherapy. 2010 Aug;30(8):823-9. doi: 10.1592/phco.30.8.823. Review.

PMID:
20653359
10.
12.

Perspectives on low-density lipoprotein cholesterol goal achievement.

Catapano AL.

Curr Med Res Opin. 2009 Feb;25(2):431-47. doi: 10.1185/03007990802631438 . Review.

PMID:
19192988
13.

Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.

Krentz AJ.

Diabetes Obes Metab. 2003 Nov;5 Suppl 1:S19-27. Review.

PMID:
14984018
14.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
15.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

16.

Statins for treatment of dyslipidemia in chronic kidney disease.

Shurraw S, Tonelli M.

Perit Dial Int. 2006 Sep-Oct;26(5):523-39. Review.

17.

Rosuvastatin in the management of hyperlipidemia.

Cheng JW.

Clin Ther. 2004 Sep;26(9):1368-87. Review.

PMID:
15531000
18.

A review of the efficacy of rosuvastatin in patients with type 2 diabetes.

Tuomilehto J, Leiter LA, Kallend D.

Int J Clin Pract Suppl. 2004 Oct;(143):30-40. Review.

PMID:
16035394
19.

Rosuvastatin: a review of its effect on atherosclerosis.

Keating GM, Robinson DM.

Am J Cardiovasc Drugs. 2008;8(2):127-46. Review.

PMID:
18422395
20.

Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA.

Barrios V, Escobar C.

Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1317-27. doi: 10.1586/erc.09.119. Review.

PMID:
19900015
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk